Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sodium valproate increases the brain isoform of glycogen phosphorylase, looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro

  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Brull, Astrid|||0000-0002-3012-451X
  • Guiu, Josep Maria
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Martin, Miguel Angel
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Andreu Périz, Antoni Lluís
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
McArdle disease, also termed 'glycogen storage disease type V', is a disorder of skeletal muscle carbohydrate metabolism caused by inherited deficiency of the muscle-specific isoform of glycogen phosphorylase (GP-MM). It is an autosomic recessive disorder that is caused by mutations in the PYGM gene and typically presents with exercise intolerance, i.e. episodes of early exertional fatigue frequently accompanied by rhabdomyolysis and myoglobinuria. Muscle biopsies from affected individuals contain subsarcolemmal deposits of glycogen. Besides GP-MM, two other GP isoforms have been described: the liver (GP-LL) and brain (GP-BB) isoforms, which are encoded by the PYGL and PYGB genes, respectively; GP-BB is the main GP isoform found in human and rat foetal tissues, including the muscle, although its postnatal expression is dramatically reduced in the vast majority of differentiated tissues with the exception of brain and heart, where it remains as the major isoform. We developed a cell culture model from knock-in McArdle mice that mimics the glycogen accumulation and GP-MM deficiency observed in skeletal muscle from individuals with McArdle disease. We treated mouse primary skeletal muscle cultures in vitro with sodium valproate (VPA), a histone deacetylase inhibitor. After VPA treatment, myotubes expressed GP-BB and a dose-dependent decrease in glycogen accumulation was also observed. Thus, this in vitro model could be useful for high-throughput screening of new drugs to treat this disease. The immortalization of these primary skeletal muscle cultures could provide a never-ending source of cells for this experimental model. Furthermore, VPA could be considered as a gene-expression modulator, allowing compensatory expression of GP-BB and decreased glycogen accumulation in skeletal muscle of individuals with McArdle disease. Summary: Use of this in vitro model showed that sodium valproate (VPA) can reverse the muscle phenotype from a McArdle-like to a normal histological and biochemical profile.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genotypic and phenotypic features of all Spanish patients with McArdle disease, a 2016 update

  • Santalla, Alfredo|||0000-0001-9418-0564
  • Nogales, Gisela|||0000-0002-7414-212X
  • Encinar, Alberto Blazquez
  • Vieitez, Irene
  • González-Quintana, Adrian
  • Serrano-Lorenzo, Pablo|||0000-0002-5661-7574
  • Consuegra-García, Inés
  • Asensio-Peña, Sara|||0000-0002-2048-5899
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Pareja-Galeano, Helios
  • Díez Bermejo, Jorge
  • Pérez Ruiz, Margarita|||0000-0001-7240-2082
  • Andreu Périz, Antoni Lluís
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Lucia, Alejandro|||0000-0002-3025-2060
We recently described the genotype/phenotype features of all Spanish patients diagnosed with McArdle disease as of January 2011 (n = 239, prevalence of ~1/167,000) (J Neurol Neurosurg Psychiatry 2012;83:322-8). Several caveats were however identified suggesting that the prevalence of the disease is actually higher. We have now updated main genotype/phenotype data, as well as potential associations within/between them, of all Spanish individuals currently diagnosed with McArdle disease (December 2016). Ninety-four new patients (all Caucasian) have been diagnosed, yielding a prevalence of ~1/139,543 individuals. Around 55% of the mutated alleles have the commonest PYGM pathogenic mutation p.R50X, whereas p.W798R and p.G205S account for 10 and 9% of the allelic variants, respectively. Seven new mutations were identified: p.H35R, p.R70C, p.R94Q, p.L132WfsX163, p.Q176P, p.R576Q, and c.244-3_244-2CA. Almost all patients show exercise intolerance, the second wind phenomenon and high serum creatine kinase activity. There is, however, heterogeneity in clinical severity, with 8% of patients being asymptomatic during normal daily life, and 21% showing limitations during daily activities and fixed muscle weakness. A major remaining challenge is one of diagnosis, which is often delayed until the third decade of life in 72% of new patients despite the vast majority (86%) reporting symptoms before 20 years. An important development is the growing proportion of those reporting a 4-year improvement in disease severity (now 34%) and following an active lifestyle (50%). Physically active patients are more likely to report an improvement after a 4-year period in the clinical course of the disease than their inactive peers (odds ratio: 13.98; 95% confidence interval: 5.6, 34.9; p < 0.001). Peak oxygen uptake is also higher in the former (20.7 ± 6.0 vs. 16.8 ± 5.3 mL/kg/min, p = 0.0013). Finally, there is no association between PYGM genotype and phenotype manifestation of the disease. The reported prevalence of McArdle disease grows exponentially despite frequent, long delays in genetic diagnosis, suggesting that many patients remain undiagnosed. Until a genetic cure is available (which is not predicted in the near future), current epidemiologic data support that adoption of an active lifestyle is the best medicine for these patients.